0001104659-21-142602.txt : 20211122 0001104659-21-142602.hdr.sgml : 20211122 20211122171241 ACCESSION NUMBER: 0001104659-21-142602 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211119 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211122 DATE AS OF CHANGE: 20211122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Twist Bioscience Corp CENTRAL INDEX KEY: 0001581280 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462058888 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38720 FILM NUMBER: 211433518 BUSINESS ADDRESS: STREET 1: 681 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 800-719-0671 MAIL ADDRESS: STREET 1: 681 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 tm2133571d3_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
November 19, 2021

Twist Bioscience Corporation

(Exact name of registrant as specified in its charter)

Delaware		001-38720		46-2058888
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

681 Gateway Boulevard

South San Francisco, CA 94080

(Address of principal executive offices, including ZIP code)

(800) 719-0671

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		TWST		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 3.02

Unregistered Sales of Equity Securities.

On November 19, 2021, Twist Bioscience Corporation (“Twist”) entered a Merger Agreement, dated as of November 19, 2021 (the “Merger Agreement”), by and among Twist, Nautilus Acquisition Sub, Inc., AbX Biologics, Inc. (d/b/a Abveris) (“Abveris”) and Shareholder Representative Services LLC (“SSR”) whereby Twist will acquire Abveris (the “Merger”). The total purchase consideration in connection with the Merger of up to $190 million includes $150 million in consideration to be issued at the closing of the transaction, consisting of shares of Twist $0.00001 par value common stock (“Twist Common Stock”) at the applicable price per share and up to $10 million in cash, subject to customary adjustments for cash, net working capital, outstanding indebtedness and unpaid transaction expenses, and up to $40 million shares of Twist Common Stock, to be issued contingent on and subject to Abveris achieving an internal revenue target for the calendar year 2022. The applicable price per share of Twist Common Stock is the average per share closing sale price of Twist Common Stock for the 30 consecutive trading day period prior to and including the date that is two trading days immediately preceding the closing date of the Merger, subject to a minimum price per share of $106.10 and a maximum price per share of $129.68.

The shares of Twist Common Stock to be issued by Twist in connection with the Merger will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. Such securities will be issued in reliance upon the exemptions from registration under the Securities Act provided by Section 4(a)(2) and/or Rule 506 of Regulation D promulgated thereunder as transactions not involving a public offering. Such securities will only be issued to “accredited investors” as that term is defined in Rule 501(a) of Regulation D. The offer and sale of such securities will be made without any general solicitation or advertising.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated November 22, 2021 titled “Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities.”

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 22, 2021	Twist Bioscience Corporation

	/s/ William E. Solis
	William E. Solis
	Senior Director, Corporate Counsel and Assistant Secretary

EX-99.1 2 tm2133571d3_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities

-- Acquisition Will Add In Vivo Antibody Discovery Platform –

-- Conference Call at 8:00am ET --

SOUTH SAN FRANCISCO, Calif. – November 22, 2021 -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it entered into a definitive agreement to acquire Abveris, (formally known as AbX Biologics, Inc.) a privately held in vivo antibody discovery services company developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders.

Abveris offers comprehensive antibody discovery and characterization services using its proprietary DiversimAb™ family of hyperimmune mouse models, the output of which can be humanized using the Twist antibody optimization solution to develop superior biologics for rapid clinical advancement.

“The addition of the Abveris discovery platform is a natural fit with Twist as it will complement and extend our biopharma antibody capabilities into mouse-based discovery and screening,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “There are three key approaches to antibody discovery: synthetic libraries, which is the specialty of Twist; in vivo discovery through animal models; and artificial intelligence models. With the anticipated acquisition of Abveris, Twist will have expertise in each, creating a robust antibody design, discovery and screening organization to serve both our partners and our internal pipeline.”

“We look forward to integrating our proprietary in vivo discovery platform with the Twist lead optimization workflow to consolidate and streamline the process of identifying the highest quality development ready drug candidates for our partners,” said Tracey Mullen, CEO of Abveris. “By combining the two highly synergistic approaches, Twist will be able to pair natural, in vivo antibody development with its industry-leading humanization and engineering capabilities to introduce a new gold standard in antibody discovery. We are thrilled to play an integral role in this revolution.”

The total purchase consideration of up to $190 million includes $150 million in consideration to be issued at the closing of the transaction, consisting of shares of Twist common stock and up to $10 million in cash, subject to customary adjustments for cash, net working capital, outstanding indebtedness and unpaid transaction expenses, and up to $40 million shares of Twist common stock, to be issued contingent on and subject to Abveris achieving an internal revenue target for the calendar year 2022. The applicable price per share of Twist common stock is the average per share closing sale price of Twist common stock for the 30 consecutive trading day period prior to and including the date that is two trading days immediately preceding the closing, and which will not fall below $106.10 or exceed $129.68.

Edgemont Partners acted as exclusive financial advisor to Abveris, and Nutter, McClennen & Fish LLP acted as legal advisor to Abveris.

Conference Call Information

The company plans to hold a conference call and live audio webcast for analysts and investors today at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company’s business, including the acquisition of Abveris. The call can be accessed by dialing (866) 688-0947 (domestic) or (409) 217-8781 (international) and refer to the conference ID 4608297. A telephonic replay of the conference call will be available beginning approximately four hours after the call through November 29, 2021 and may be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international). The replay conference ID is 4608297. The webcast replay will be available for two weeks. If a participant will be listen-only, they are encouraged to listen via the webcast on Twist’s investor page.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including but not limited to the closing of the acquisition of Abveris, the successful integration of Abveris into Twist and Twist’s payment of up to $40 million as a result of Abveris achieving internal revenue targets, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; the retention of employees of acquired companies and the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits, risks of third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 9, 2021, and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACTS:

Twist Bioscience

Angela Bitting
SVP, Corporate Affairs
925-202-6211

media@twistbioscience.com

EX-101.SCH 3 twst-20211119.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 twst-20211119_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 twst-20211119_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2133571d3_ex99-1img001.jpg GRAPHIC begin 644 tm2133571d3_ex99-1img001.jpg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tm2133571d3_8k_htm.xml IDEA: XBRL DOCUMENT 0001581280 2021-11-19 2021-11-19 iso4217:USD shares iso4217:USD shares 0001581280 false 8-K 2021-11-19 Twist Bioscience Corporation DE 001-38720 46-2058888 681 Gateway Boulevard South San Francisco CA 94080 800 719-0671 false false false false Common Stock TWST NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 19, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 19, 2021
Entity File Number	001-38720
Entity Registrant Name	Twist Bioscience Corporation
Entity Central Index Key	0001581280
Entity Tax Identification Number	46-2058888
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	681 Gateway Boulevard
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	800
Local Phone Number	719-0671
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	TWST
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://twistbioscience.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2133571d3_8k.htm tm2133571d3_ex99-1.htm twst-20211119.xsd twst-20211119_lab.xml twst-20211119_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2133571d3_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2133571d3_8k.htm" ] }, "labelLink": { "local": [ "twst-20211119_lab.xml" ] }, "presentationLink": { "local": [ "twst-20211119_pre.xml" ] }, "schema": { "local": [ "twst-20211119.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "TWST", "nsuri": "http://twistbioscience.com/20211119", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2133571d3_8k.htm", "contextRef": "From2021-11-19to2021-11-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://twistbioscience.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2133571d3_8k.htm", "contextRef": "From2021-11-19to2021-11-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://twistbioscience.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-142602-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-142602-xbrl.zip M4$L#!!0 ( ).)=E,&&M[,?10 /=L 2 =&TR,3,S-3])S YC7A#3E'@*DH4U(%DC3]DN.; MPXQ=J MV0'ZZY\9R08;3 ()R;:[[78;L*29T;QI9B0YQ_^;6":Y9RXW'/M=*I=14H39 MFJ,;]N!=RO?ZZ'-,,, MV>>3SOF\NY?&3CWC\(Y M3!=R(9PEX<1GBLTJY3..ZVR!W2%.:( 1^1E5QIG%<=D [/'_I=/DU&"F?D2Z MS'M+VM1B1V2B3]Z25D-\N%7RM=OK[A_YQOM:[0I^('DDG5YW=.'D%F=\FS#3 MVW"F&X K%F>CGC*\I-PRT#Z8!OQMVL#(:1TXY%*S9>ML\I%-;Q7P4*7#7/Y0 MV01N)0*W9C%;A_^]4Y,.;OO4Y&P#4.438'?C-G<;. X)$QYM B-_VQU2E_'; M_*WPDQ((%\\V@=- 6JX"6(4EDE8"5QU]2K@W-=F[5!^T\(CDE)%'>H8%7=IL M3#J.1>U]^6 ?"'"-OM!WW;@/Q^D&'YET>D1LQV:BT9@(R%RU"?#-TG=G" M/O K=&S[%L#2I.I/O YZEE/7L80=YN!OQ7/FGU/$AED#*F8<)6I#JCI7A^-L M#,5SL$HG^RX%COE(=< )45NH292>F!:EJJ(]D81LC!%($7A,YJ*5<=D#'?,1 M%RLND$;$,GHT%%[7&W,O'1I29L+U5-#L@0=YE^*&-3*9]!H!JCAPB8X[OAMB M@VY"*XX"9A!#?Y 9H7<+AS$AA]G3V7-#QY:^P5PBIL(2E[-ZZV-<9HN#Y^BR MB?@";"/@KZ,O4P$QA>LUJ,>J\RF$D.9M2\- E"L&A2V+9,4("!\&+(WSV;<- MR60PR"5N6HQRWV75P'*/H$\(+&R*HT!H*^!+-[ 21< $T>G)..;N9@D/N 80 MXS)O<:PP".HY;J1YEJ+N@/#/B)*"H*+D6B.+@\=WV3I*SH0JUC40\MQ M:<\9@7_/CV 1"9ZHCN6MG%_P;V0*V=@<'I_]:&'Q M.GQL\0JG#F"@J_*6H)VFJ6D,X)$&/H:Y %ZM7K=;O6:#='NU7K,+PE%? 6>W M6;_NM'HM0%AK-TCS<_VLUG[?)/7+BXM6M]NZ;#],R*,K][J$W% ^A+32;59:?W2@9^Y;OV0N_,PK1 M >,>8??0F;BBF>EOCE57A/1 TX*;*"^XB2L1AC9ED)KL+ZR26;IKEES>*SW9 M8403(ATP63!NJ-/I%&; ["2'$B,L56T[]\Q2(3?(5?8)0O[M9QY"DB]N2_46 M%:@9*)!,ISML8'"L*WI87DC6GZ)U94]Z[;O*N+"%!2<);ZK:P^H3.9F5GTC= M<<$61*%S,TW9MNGN-2<4G!). "W6G1%.*"=\Q#3,6G5B (\]OKL#?@PLV%WE M2O_V>NQ1U630:)H@)$WL42@I\7U$=3W\OC$AD1QEEGIHCFG2$8<$(_PD4])C M+\S*CCT]1!5@AZED\B7,>NZ9ZQD:->LBZ+UW5'7V&-D[.&U1H6S_,76_'FN.^ A1&/C5SG M'K4\[L[7H#-5;3"3CF$A6&&ITA2"CY[^!.%(>YFKP1]SO7L2O,V%G7^*L$]C MPCXU3 :<@44P6;*G]_1'VSP9?Z']K?G9.4ZLNN72A<.#_%*A]&\DIB?99"$F MIAZ=M()JI";T_2&9E5K=:?Z;GV^Q;UN3V0H"4M5B.0T)^2'\65."$_[/)<8 M%OE><'T5[@13$ >2 I=\@YR ZX;(3<(P&-9=(^J!WH2+Z[/T]/G*^0K80::-)$J\0_B0RM#.AG2S9"F-3*=*7-#=L1-A;2=3)PKV%] O)4M7R8(^_!QL=T M2DXT/2!7I/(>W0#*XY*]S__E)1L9PT+^%P+]TKB/? JZX(,Z^<"[?_21F:Y]M; MV)+QIZKUVLH4;V$^)TGSN7(@?C6_&J/50?-=;Y)OW;3]L\G3@^85LXEA3U4K M165Y)_IUE7LOH S3U9$++#9&U"1LPC3?,^XQBP5OB5"AR?31N>_N?&U= 2-T M]BHEP-=RE'N+ZG,0J ^:5\UE=+7"G+/>G^]O)N/RZ1;T)8HN53U45@7@;Y;T M/2S6G#NPX%X-'?O!!.*F^>=AHWJ>I"KI)7RP8:ENZU+=5X[ M^L^_#O.Y@[<."S(/ MJF&N*"3 5RH=#G"]3V0A'$'].V[.R;E85W['UL3>RX26"&'#'B"FR9T-'(= M\.J8,ZG.A*C,=,;(=VQ$Z9##]$?2-TQ0?6)PL ./V3K3=W<\!V1B^:9';>;X MW)P2#B$S[T_%T&"$H\),9"0=[-)$"IX^ )AV].PK>^8@!W'8?'(P"R%'VUQ MVC]E;3%$\% >]$#Z%& K_K%4V4BJ7/2I99C3(W(#,! .3ZV,76]$0S>ML]'[\NDW7]O*CM"J(W*))$FQ'KY=6<,0/S9*2==@9+0U( NF M&J6+C"*;HW@CXAB077K:7=/XVA[7, MH1Z80Q<6#PW$90\NP%>"PS23;:$SN2SQ4O&LU*0O:@O+]/SUAC"G"51-$K5L M!;DB3>?R$4.(;=;/S*"H9&3/-[\-X:L, VM):A+A'EXI<44_G]]0WZYF)[/O;4'X. M0SE,-I06YSYS'S67BT;E3AN<35RU\IKFLD3=KV@T!98N[FGK&4W0][?1)&_A M+$ES(:M6%[/J!6F'/W+"Q(:&Q](X78:W>\8NW70?MKC./FP/K\G)8W#:D&@F MY7S3/>B']ZZ>R ,E$W4T8NO_I?>W>BY%2L)-K>[44AUSCV^ZP;?FQONOPY=V M<.Q*: @+G,-L6]A&384&6:-@+M-7;/V]Z(F@)YPX"/=E@IQRFLNKPAB2EY@? MW?:7>K_<_]C?QD;3(LY4%=<5X&77<[2[%SX;\DH'0IX@DK#4'EBBM,!D>5S; MO-/_8O1KE:>GC'-YQ!"FJG@9]Q\KA-R"783AP.K#J:?*M5O[\;5\H6REE"6. MPZ&?63X)ET03B N"EC;E.OU.WIN."@ETEYD,@I<+ZMXQ;^.#.B\8R#P?8,O6 M,9IC1)T2392DH<,=.&$FCNXLE(L-3D"X$ HBC $9N,[8&^[N0%0XPAHRY41G M?<.6AV=EP4TID>7+ ?,[ 06RAW,Z>"NK;F%O0 0B&8ECMXX;Q)9Y-9U/ !9* M;WM5@!A8CS?G(".#,RY6UGP^P&>@GXO(-N<7PZ_&\&4SH0<(6R\)"CF_>,WRYQ%HJY]@.J%8<7,ST0Z-Q1V;W9TA6)GP M1V!EMB-2+Y\ST0W$(7:&B'BMB"'V?.2E9I2"0&9.$?O8 -RH3C90#RTNNS95W@VN[D= ^<;,U]=VM\HK1/$6^G_WL;H 8"4^ M$;HL3WWE5O*C%Z++(C!9OGH<9<6H&M[27D+O,GJ75AG8#] X$C1'4997"'-3 ME%$);)GYOU3Q8[.*H9(Y*!GV&E%IRV.6Y$,AH^0W+TD\BN#:GF>LI$M-)LYJ M-;_[L*Y%@I4,^47CQ$L\A[MPWP^&/'#'"R.PPWP>J(CR3N04.M."3D>R4(CO MPPINC,VJFC V]_;-[HY(/("IE%S V@GH:P.7B6KD/L%[BSJ&G<#K)?+('BY$ M 1&+8T/X^[C@POI&*.3+ SFA?0C_?<\P?0Q408)R)=W=Z?KJ/FG96F:?U-3/ M.&W3&1@:EP_)GIY5LQ2:0*<-_F;S^00UW$=%\@1@S72X.#DC0QD13%&!?%^.YE[0 M'+R "3X)7NWN_%O)*/@J'%@I7')/39^)DKF#_'%@X7J:39!X.6=!/;SP%%%X M<&P$\3'#P$_2)Q0HY%"<%90/]W=WN*]^P_P6.F@^T FF#S:A?X//:"I-[(D84YY. =!6,TL;3J@*Q/:*&'F4BA*DC9G/T M-1'*BLKN3DC: EMCT]^/BPRS$,"+>Q/0 ^%%9A-J*]6&!D2X0!ZF1>A/;- V M%V]H@X \\'0P+9RDD#XX;XQW=W?P)C1ZDKS4T06,Z^;,A<8<&/C7!0\F/"RFX.1<"T.$RT\#7DH*K<>P@40Y0<(DC1M!*OL_27W4:)KV[ M.T5(>O?R8I7.AI6JDE*6KX88^*:$V<#!EF\.1,""I346'+WD4=?(!3<-^]XQ MI;N")5$%ODCNPI,5TW5L$^0TGS2H8: +D,>#5(0, "P#[^[R0,("-WH%4#<+ M7<-B[:ZDY(*,/CH3Z0P%0=+?4KGCQ^.$H9I+05A49V+5AG5"%!W 6X-'-$4& MIQG>7 UTD0V@S]FF%W@X=@]]1*SJ\$]/DBH9)?<"2=+IK+PD_($,+E"'FI.A MH1K>KYL>X9MV9I/XIQZ77GEP85DSUSJ-,"-KG9,' ?N&632J5 M="XS]*R9WN*&71IF[,*:> 1+M9#K8Y.L5#*YV;3H<]]VL'*5V-KNZ@NSXTK< M%NPPDV$Z+ M[#A:M_6^7>M==QY[->Q?/H-4[%6/,BN>Y\$/G(N(OH%Q7Y:3(D#"D9A]38 0DDMB@@TQJ88P 1WU(^%QP M!/K?.1Z6Z\3SCUH%&$N/O^P(W[UX%%O+@W+9R]:*]:/^5']@[5. S_X M"L#$./0QABZL8&MV7!/XBC?AK,+XF)-_#NM3U2S/DALLB%.+-#,$+W9Q\N)S MVJJZ/'IK=]VW.3%'GJ'' MEL.36W'\2MR8C_R^%_9A]XVKNF)K][WSRZ;5FO@J9^[[<8'_=.=UOQ@'7R] M:7P_J]6'=OM458P"4WJ'YY]KU@&]-#^?-?Y;:_<.!Y/RUV'1-]N'5].[DGI^ M3L6)5 MIJ>-7D,IV5\_WG_X4&\T:&.:;7TIW36:_>^Y#U=%U3@[OQZ>7@P'WYJF;W?Z MEL)R9K-1GCCJ0?[36>5#]N2D\M]6MS-^)]GQ_U!+ P04 " "3B793&6!K M-^L. "V+P %@ '1M,C$S,S4W,60S7V5X.3DM,2YH=&W=6FM/'$<6_3[2 M_(=:*[*,-#,PV& P+-KAX00)8\?@9/-I5=U=,UVANZK=50V>:'_\GGNK7P.# M-Y&\$=E(,=!=CUOW<>ZYM_KPA^MW%T?#P>$/9[-3_!3TW^'U^?7%V='A9OB) MMYOUZ\/C]Z>_B*OK7R[._OYL;HU_(Z9;A1?7.E=.7*H[\='FTHS"@Y&X4J6> M/\-$3/W0S,MEN=#FC<#$9T?/3>2*@\/-#_<&>?7%CV6F%QA8ZD7J#\3*O,/C MH[,OJ8ZT%_O[D^GAYO'1PT7^\$ZQ,EZ5S59C;PN>W#Z(K/]N/IX M@B7R[>G+ESNOI\G+?ZDO^_OCJT M)+8.Q,/3L>ZN[[3SXEA;%VME8B7.Z)43VG@K3M5<&^WUK1*S1:E4CGG# 5[, MXL^5+O$TNL5FV//89@[SM%G06D4JRUR*$UG(2&=80+GU=OFFI_FS5#8>A_,[ M',P:\;/.,C%+$G%X?G1NQ$_ZUHK#S?.CF?$ZLLER.#C5+K90U%)\R*2?VS(7 MSTTB77KP_Z65$VOFJF0O.I%0BO1B[\W6ELS%V;7 ^[_>:9\=7;W_=/V#N)I= MBKS^PAH,36Q:VE.PT M+RYG5Z>S']^(ZY^OKC=&0HK8YH4T2Z&,C#**H[AR@!B*102E$+H4TQE:0,<$PP9JD7PD!I$@Z#) -!I!$\CX$O* 58?:EN#'VS@CI\.Z? MI(',+G2,$>AD.*HP< 6Q4$;5ZH5&HF[?6,$9,:R4A29+W\HXUH9^DR;!+G)A MK(.ZW' .0I9>BSD4EV(.^U3L !YY++ 0GE>&25R6SGZ-U$9!":#V&3M$X@5VMF6G0L(N*8@Z^.,B"T=PYPR MN95P>7+G)VW(YUGRN;('U]"$3!+=N#=IIK%Q9\4FL 6>2F&DKTJ9#0=SA#6[ M<@ E1"8_0%207V0AILD#$$8*/VQ5]MR]U7S\@&$DSH9#L[8/]Y-Q(6")P'B1N)#.CF= %3/W@\#Z- MW58A0!^)_X&)2HD;A8T+K"GC5#%F/O3R-QTT#@>9CDI9,B $'X3.2*NN4+&6 MF5^VVQ_T$(I3>W?4!H_AM<"^VL4/^!R $3W7M!3I"A"D%YP:PY@)> ,,@@V# M:\>Z "0F 59=:^8678,>V&:I1 BK+W!RKQ%6$$SAS("Y4B$H$#52E#:JR-"M M!I1#FAP]9B-ARP7%71WUE&\0^$J Y:;L# TF\C1Z0"7L@MYJ=AH,UT797F[*V$N6'59BZL^7- M/+-WM!_ MLRQ+QE1#0<>.(ZH+OQ5_!:Z#TB@Z>R%UV<#2Z/&\WSL6JY;RCC8)7+IHQCUQ FS5H@1!M 0;G M4.PIL#D%3^,Q&4(MXQCT*?"C5+=U0OHKQ /E%&\]17%5(OD#3,@YX78=C:H* M.O5WT_TM >3.Z*DV<58!48:#[Z8[_3*^=JPC7/+M.G%E74U;VI%(: M!\J!X:,PV_GZM4/R4:Y+ 7#!G!*^M_$-FYLE(QE610 C'X$"1+^JF'EJH-$4 MR#+Y%;^35X6X"$.-\AR>3+E!$3QY)N@)^P:3'J2B"-!L*"IY8U-0\/1D'PX( MCHUK*&6MM%>=9%\[S6A54U #Z8"GYS^M=OM"9W&ZO::UN$O/(EL" M3]MGQYE$"$VQ.5,("/#?NH>'F]ASS?81^,+-.%((1\A8L,Q]D7;72$1B_M$M M>XK9),T$93Q1:QX?W6]AG1ON:G ^^Z;MJ_]1.F_Z(Z IAGE/2CR'NDOMN6)N MS2$V,VX% %2MN%,1LB&J;$)GB4RR=-[5N'L+RFFY"\6MHM#3$W*23\29I*:O M8;&X @=UJIQCOM:! Q)?E=7+@2#>@B$0@ZH*1G$B"IW@STM'K G<(J(. %+N MZ![TKR^00C[CH]6M!!D3C0:V1$3I)+?47NSM[FZ(W;V]\=;^J]?B16*A3E#7 M#0+Z%Z^V]C?$]O3U>._UWE2\J),J;22SC0!GI8(6Z:1!Y%:GYZ?BU>[6WO;^ MZXF8">0=5:36Z!@3F##6=.>^%5IZ?"MUQFDX4K H$VTFTU]057(6FQ.)3_$/ M-"/G7K5Y/6M+T*X+N5]W(4GB'+L_JHV=G0VQM[,_WM[:V7VHC5<;8N?EZ_'+ M5UN[][7!ZAX.ZM.M*@(9N=4%&:7VK485#\_,C.".G%#=P)#GG1P]T5I[YA-MIWLT,M;AC $ M.;8Y]?4:N&,JB *F*1V)4A :E57![)+ZX&$M5!A=W5%!*_A0*\5T9V M?>1E#3 V4&-NVZPVV_HM Z_BU/"T(%D!"RDF45Q[YLJGX+=8!XJKYJ! 5;EZ M6I(7D5H7X'>EIHJ@*=WI)54&73\?Q4 QJ?U#$Y5B?MYT;"NC/U--T!/*]G:F MBCA"W4[:1]G!M5=?D+J]5W#Y[%?PN!M'O7?B?-[:+%17U)(?]UKR+A B!I[+ M[Z\VB)@CRF6H_;AAUE3@;6>.%^*6QFKCJM<@Z!U;9LY2)>LJ[@!D%J(KT[0NL=Z"*CTJ)"05)ES.X#GIEG;H6L>KVS?;Y?)&N58G+">UN&5< M6N2_G'RR\2S%UPJ-RE(E,Y_&0*Y1S_=$G*JJMS:B JE#KFGKQ3Q3]5 8<;GZJ-_QW^^JMC%5D[FQ-/ M'LNITX7H==3O GJ'MI&7VKBFISK.ZE.Y]E0@1DCCW=_#@:4K.0)(TWL<+C,I M(OF6AB#*-,YUK'WIT:QI-C[75&95UC>"5 M<>&RH[X\04BN4HE"+KE5V77+>HT?2: ?&'!_P:Y_T_1NB$WUFS>$!*7ZBD*) MC&8J]FUKHRI+$B-2F59S5]_G%!C!QW%UO@'0L;0Y4"6@I0P7NGSW(>?01RK+ MR):!J[MF*KW^$"YNX1?8+&#I!7XL@KX^*LZ&LYA/.MW?WYF(JRI.OW8&T#"; M(4'75\;<7>/?H0[M;J $NI-^VUX#@Z)TPGX1@S(NX;C-.X:6C.$0\GI,Z(/\^9[F+CTN:"L'Y>,5S_ MKA7)*&4@XY9/ 7,Q+R<-?R5^A@-6)JNEUE1/,TU7%AK*+?D]Z:B^;'UL2A,; MW"=G5B"]IQM@9BG=]P>A\J%I].MP0.R,&WTN:$!]J=NV[92#K^W9D+P8D<\D MI64F-*"]AN06$Q$\$ Q?=W?7\$&P_RSA?-Q2OOWQ(:O;)"9ZD[NMRSNGQ%:JGF=)E:?WR"D9XZXD1O^]XSH;0*P)U7)?D_W9"YN-1%_];\,<]D MV8(W!?Q8A8G0WZ#(#TX/"N]4+Y;Y"@@,[2LA3#U1AY*4^B^NE@,9-%P[M@EF MC6*:7@AM$BAU-B([/3Z#M=W@H@M7 7219IK/*=;,^;&""ZD2GOE1$;22+G,0 MA/&/8J[I^JN]YNSA/^GQ[ N',A6D>:Z=8V4;,:L6= E==R-&S55&* 0\K8ES M(W:Z9<].P!((3A]/&!T5:.[<5IF(*Y2\$=0C(!W7)F7U[/3JZOWCQUNKKF(]=O+/(,OI])K.\ID@^//V+AJY\^C-H& MC1*S^5SJTH5W^]L[8X3$>'=[.OV6!_UTQ-=>__!TW*C[9 99Y$T:[A6 T# 7691^BD:]P,S:/A<:]GH,.#3Q^1>CJ?31.=$O"] M-CIAKMFC8[:/?N( VN@,*' L&=]'M]B/M(6=$A\X.F9!Z(,$Y<@BM=&>Y31& MR#37T+T%ZC%^,^B5ND]2AJ)MVW$<6Y2]X)CQJ;!<%JPG.)181J)4:R2-_%F/ M?D&$6Y)W\-%>_#49D/L)T&]1'^\^NG=XYVHXNO1^/PYVSAZFB0R^.R,O>*:O M#U-(SN%N&+N7K>;9C_O>>1:R(]PG"#!2AT%%U]#UY>7%NQ;C$[O9:#CV_45_ MF.*,#-A.?$*G57"GU6K9J;> +B&3$?<+Z5U;NT=80*FLO*0&3ZB0F+IO\)XL M"?/@/3MSOH&22NB7#$H*J <+. &N-6$OMG(H?-,I@)$P)QB')7B,Q2@5S1TI MV&PXYFY)$5PNPY6Q&FK*UQ!$)2%S5="N[X;7)4/&1,@18<(E:KY -VM*44]+ MC9P/ 5!YRGAP F,<^2JWYPC[9$S ,Y#$? )2=Y\(L0OKB1:=C"EEJN'5U.46 M;0M#HCI:&3YT]-&W.?/A6M6!]$*-6FT(C;&/F;HU#$2\KI$MM9B23N4\&!-* MTICY:#G(U(,4Z3+5,J5T[$7PG$0DP+ND!^DZY" 4+RVBKPPY,8>L(+G8=R-_ M,\XLE4I*;B@V:[9]Q?@,8(S2L6OKIN@:@NB+S\AM3QS&74/&0IK%*?U2I5FJ M70J(EJX9NW3G%W'J:/*95PBNC2<=9=F=MWWF9M* MU5#TFUGP3&TRG::Z8ZQ$>+-,-TEBM@.;)5'PMDABQ=5=%5^L@NM%VD+K!JW] M!-2&KF3:X$M16,R9UC;I+'\PWI%/*K9%0F^.V9/;Q8>KY+DT\CM=]RMZ^G1URL)R?' MQ]/)/W^Y7D2/9(/'"5/'+2(C':5JL<5-S\[.)GFIEK:4NY6@>A^G$VVGJEF6 M)AWZFI,T.4]S>]<\PEG>[;V[0:!"_6^L96.U:3P]&9].CW9I/-('/S^"@E-R M3QY0WLSS;/\L44H31<*HW/8HR(/=#!5BHN(GC*QQ1F*UHS.UH^D_U([^4FZ^ MQBM"1T@I)1]@N\X:=95!$]=F[XA(>'S)WN?:C/9D7WYW1/8_-* >[[P)2YYA M^B[S]4CGMF_(^X[X(<[]D9;C/'G?D:Y%_E]L9VW+;SZ\]N-*U<9K^:EAD>PR M.8&16)M4572,P/D>\HFAK+NJG4>->JD:S;EHMUW-C'F=*8F.UOQE$I-$UGTR M51_&ZD/>;/F?/V9F):6\$-H7%E%/XTK%).)R M:GK.QK0XC$7X@^ ;ZV[+5G-+X1]T5<47AT7N C#:D F2\JV(R)MZI>X6.DJE MHPV5"K6D(FS\=3'Z(=>@W[7J/Q\GAUH<=+1< FTWA&5+6:.E!:=;3+;ZOJ8)"X&V,9B$FM;3P'Y/UHF:6I0% M=7Y+U,:.80S0NQ[Z.VV;L1-!][U0M)2NN0"LFF@8LJ#HL'L# M :GD?AE9"LS21 U@O9"TITP(9-7MK*H(@![8',Y!&H# D'F\L7M3J7RZ2!C:WI?<+3LMW%3R4. M%B'3X4"*\C"DXCR15+L-T<-02^F:'L"JR8TA"XH8NS>0E4*.E':T@\L+:MV5"I9@*"8WOHP47HOD,RV0C1 ,73#'3)LB3;J^?I;K:;%1&6QK4EKMB MS&DFS/(@6 !,F0P4,J1TJ!!ZZ7E]EX!EZB%&L#FFS"T!=I--"IJ:@$BP&@-H M.&CS9TJ]$#&3(Y/ =,YBLON9[,%VM71NF0!L-J$P1 %187<&8%&*4:Y&4NX% MC#N1;+#8+Y*H9ZIH"]VB 1EMLF&J H(#L ;04:K18C[S.9,L\6X>2U"3AZ1X M'KR'$E#O%I8>VTUF '% Z'0[! B20:@9Y1.D.8NX>.:UQQUF?"L'P/V,Q_ * MI2?*+52#FM!$JS,D(,"&^ 0P:X1^*)Y)05R]QY-7@%0-7HB[B&-YH-+RG^N$ MD2G8?JO6+5T==IM,680!D02[ _@IE1_T!Z1BT"T+!9J3-S3UQ#\T)T.A.0D: MFI/W0+-\Y8% <_J&II[ZA^9T*#2G04-S^BYH9,=['6MF\N.M6/)7V\/9H-(+ M,FVK5F .LO!P:7GK@T4%J/6,"O&)2;ZPNA5W@K\D+(*7S)#<"S" :2LUAC8\ M=.P&^_BI%L0ZSNM84RS*>[\D6N9GE&F:M \QA28\2)K&>@>70NT3B3N>9IC^ M.WGN/!&WB[W@835LA:2A# \5F[T^8(H8)(-\G%B7N*H;&M97R8QR=Z\ 6VP= M7@&N%08!@<8WFRTK[_+8GAL$=*YZN=.F M[G&K*(C>[W)FDE!J45/L&(L%ITF49 E;_R)//D6";:VRB5P! 1O4-+050: MVC(Y. B15CJ&X$X0!2&1'9&_!*@2"XG;AP?K;-\E=@5%OV$-!ZP, I)>>R8L M,F $((- ^ U-*'B!-DLA>J(M G6PL2;>7\ MN)^>K)9)1FTGEVV)LSD),%?-2$9Y$&P IDP6\C+$']#TY*^KOR$=Y;C[;_A2 M8)4\=K'?K#@%LD]95:X@Z+"H.;!(@D !]F72<,-1*46%UD=VJH992W.,M+W^CKST-^9>[Z%&:(L +"7:9ZZ'?9M(<_NN:(!#H,-8Z M*2FE2&M]O)!PF++6_8N M;=%P+IG$; .<1&P'KH(6'M;!.C=%BE"Y+ATNZ+) M&@/)"3O5KJ'HL&SR89$&A0KL#QPSJA!TB'&=T3)/<:;2\XM-OO\K^<'22D#G M+*=EE\TJJ:5-% 0C7@/;"\E=OU39 M9=I\F]*F#0BA3H/@^Y-5C$H5@S53WE+&B)E<:JUYQU/BALI]XIB6Q7;NF$H2 M$!XV7QT99 326B\L+#:8TL_;-&$DA2 M6+C<$+&6T]M/@K]FCV5^5K!M@-HM&YV6FXQ8I0&QTN4/8$:'H")&I]3U \_N MD%"\R+((M]0B=8P-:-9@IJ4+"1C(7(L62B)UO>6&9VC)T=>4H.R1H,OR9^CJ MF>"+>GS]TD@4J17N(U1(Y7QA:#QL*XI@B"$= 6M"RN_U: G]QYVQ5-HBO*,7R5I:%QG#&O M;<](EG<0!$1 VQ64(B\7HESII?\_8_8DML]9M+\3/")$/6655J-5W_6W@=%N MF7E3DYHT#0H-B+.W^ 4(/%2!:G5\J,U8/B_FJ8?&538W'CTM'K$\@+?;+%4S MJ#0&7P7O#')\>V% XR;#!T1 :$WP"9TPR&/1'GH!U0$HUJTI_.S]) %D,2? M]_?D@0CUWL&2[++/JEJ%X!6JEG MQ,HJT.^J$I378OO]\OJF:_E);M:;Y%\KG!*YY;]02P,$% @ DXEV4S(J M68M9!P XU< !4 !T=W-T+3(P,C$Q,3$Y7W!R92YX;6S-G$USVS80AN^= MZ7]@U;,LRV[:VK&;L14KHXD3NY:2M+UD(!*2, 8!#0!:TK\O0(J*/@AP=>': M!UNF%L"^SX(@EP!X]6Z9\NB%*LVDN&YU3TY;$16Q3)B87K>^#-LWP]Y@T(JT M(2(A7 IZW1*R]>ZOGW^*[,_5+^UVU&>4)Y?1>QFW!V(BWT:?24HOHP]44$6, M5&^CKX1G[HCL,TY5U)/IG%-#[1=%PY?1FY/NZ3AJMP'U?J4BD>K+TV!3[\R8 MN;[L=!:+Q8F0+V0AU;,^B64*JW!HB,GTIK;3Y>GZIRA^Q9EXOG2_QD33R/(2 M^G*IV77+M;MN=G%^(M6T= M_-O2],!R.5:\;..\4[JSJ=E^RP+V6YYH=JES]^YE3$P>]MIF(J^%^Z]=FK7= MH7;WK'W>/5GJI%7"SPDJR>D3G43NKXW>IE6S8-J,F=0QLSV/NKAUG$VG)VV_ MM [GI6>*3JY;9J&-;>2L:W\N7!._[AB9U=SV3\U<]VI%G9WFYXIJ*DRN^-X> MV"E"E\;V*IJ4%;GVCW30,./*K+M.-VJ[?I:EMDG[L;!<^U-ZQ&6\XP1W\9![ MBLN^G5/7-#Z9RI=.0EG'47 ?5Y_=^MS9Y) MIP&O2A(C6V.U4[L6^SYMQ^Y&Q9%4"566=5D74?%.Q Z[Z=JB,R?*5M2.9XQO M@CU1,O7169.0'D>W0=DFFJ%Y8]M/G ]]3J;5./=,@#R[&$ KU6 1?4]UK-C< M<:D!NV,)Y'N&RK="6\.8RW/GB4Z9\]>YXBZ^U!T,CPN>(D#PYY@C15 M4@1N MA,@(?Z)SJ6K [UH">?^&R;M*&Q+FOS.B#%5\!2%]8 R$_083MDGF5/1#['YC8_3I? ?B[%W=]MY<6 M./NM(D#\?[X6_ =JD2+P2!63B;VD*P#[ V,@]0M,ZAZ%J+SO1 *EO3$%YS_X ML/?D(:'N,QT37GC4M\=T&'>%.10Y2LY9*Q,5^[^4*##T+6,HDNZT,K*&.4I-,G"H5M M^:1!&#>Q$>*[;PEEC))KAL2A<.Y9/8KP@4CH\B-=A4 ?F$))H^2807DHJ!\5 M2XE:#5ES*SY^.J)Y/@D%Y3$!H.E'SS".DH0;E)$HM+K__<,T&[H5!4FH/G MB/ "$)#Y2K"?'8?]#(X=)0^ME?E*L)\?A_T&:@ MO<90Y"BY:(U$3.#YE>9!/2KYPHH54G74#TI T2.FJ&&QJ!V^N,A#>GMI">6- MF*Y6B\/D_"BU(?P_-J^[DZRVAS)'3%Q#0IM^P%C$W3VT\"TEVC.!\D7)52OE M-(W415A1XN^^NQ90H"@):)68AGG>2S?W,9,B^#SVT K*%263](EJ>N!UZXFU M]]3?^AJ\@@UE6-V7T3#&;XH9ZT%/IFDFUL]H/+-B'E,H7I3T+RBO8=1#R5G, M#!/33_8.43'"JSE7V4$AHR1[?F$-$WY4U$7:;2'(UW&Y#0?J83+QC;PA>RAQ ME%RO7B@N^8'6&57'\J\H!8T"2MH'%=WT.$/CS Y[J^[9>.1VS'A&F0,K*&N4 ME,\GJF&VG^5($;=S;[A*QY+[MX=4&D()HR1X 6D-0][QHQKOG@D4+$IF5RD' M:4RX6\8S(J;4OWJAVA(*&"73"XE#&WNGH+%W>N38BY+Q^40AL2W6AMLSZF', MV93X=Y(%"X#WV6 2#TAM>O]>ON7'[>E6:>Y'WWZHQNXQA0+'V2(9DM>3AK+XM%S9MK3_'R MCA!Q7PDH>,1)Q+!8I/5IACJ?V0M]3PQ9>QCB[RL!Y8\XH1@6B[9^7O7LA6X90VHA+82NEH4 >IH3SVTPS075P;-DSA$)&7/-:*0T%\EU*U=0.:A^4 M7)C9>F]G"+:G !0ZXLK6H%0<^,L?^\B+_6]!\A76X+<3(&+WBL1Z[48/6H9$RIFS[1F[,-D! !*X"&!#$_/0H%SN,"F:9N,Y&,GXZ(0JMTQA1)?FUC;T'+XI A2'Q@?U MC4)@#!5ANNH MS'T4 #W; $@ @ $ =&TR,3,S-3